Effect of N-acetylcystein in myocardial infarction

Evaluation of N-acetylcystein on biomarkers of platelet activation and coronary reperfusion in patients undergoing percutaneous coronary intervention

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201210118698N2

Enrollment

100

Registered

2012-11-02

Start date

2011-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction. Acute myocardial infarction

Interventions

Intervention 1: The patients in Intervention group were adminitered to take 100 mg/kg Iv bolus N-acetylcystein and then intracoronary and 10mg/kg/h over 12 hours after percutaneous coronary interventi

Treatment - Drugs

The patients in Intervention group were adminitered to take 100 mg/kg Iv bolus N-acetylcystein and then intracoronary and 10mg/kg/h over 12 hours after percutaneous coronary intervention

Standard regimen for Primary percutaneous coronary intervention (Heparin,Clopidogerel ,ASA )

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria:Myocardial infarction patients who were candidate of primary PCI . Exclusion Criteria:rescue pci; emergency for cardiac bypass ; cardiogenic shock; life expactancy less than 6 months; Age less than 18 years old; Uncontrolled hypertension; Thrombocytopenia; Malformation or aneurysm; sever chronic renal failure; Sever liver failure; treatment with glycoprotein IIb/IIIa inhibitors during PCI ; sensitivity to sulfonamides ; Major surjery; Unsatisfactory to enter to study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
IL-10 biomarker of stenosis. Timepoint: after intervention. Method of measurement: Serum concentration ng/ml.;TGF-ß biomarker of stenosis. Timepoint: after intervention. Method of measurement: serum concentration ng/ml.;CD40L biomarker of restenosis. Timepoint: after intervention. Method of measurement: serum concentration ng/ml.;P-selectin biomarker of restenosis. Timepoint: After intervention. Method of measurement: serum concentration ng/ml.	—

Measure

Time frame

IL-10 biomarker of stenosis. Timepoint: after intervention. Method of measurement: Serum concentration ng/ml.;TGF-ß biomarker of stenosis. Timepoint: after intervention. Method of measurement: serum concentration ng/ml.;CD40L biomarker of restenosis. Timepoint: after intervention. Method of measurement: serum concentration ng/ml.;P-selectin biomarker of restenosis. Timepoint: After intervention. Method of measurement: serum concentration ng/ml.

—

Secondary

Measure	Time frame
TIMI a score of coronary blood flow. Timepoint: after intervention. Method of measurement: number.;MBG a score of coronary blood flow. Timepoint: after intervention. Method of measurement: number.;MACE. Timepoint: 30-daye after intervention. Method of measurement: observation.;Added at 2014-08-03: Major Adverse cardiac events. Timepoint: Added at 2014-08-03: 30 days and 2 years. Method of measurement: Added at 2014-08-03: call to patient.	—

Measure

Time frame

TIMI a score of coronary blood flow. Timepoint: after intervention. Method of measurement: number.;MBG a score of coronary blood flow. Timepoint: after intervention. Method of measurement: number.;MACE. Timepoint: 30-daye after intervention. Method of measurement: observation.;Added at 2014-08-03: Major Adverse cardiac events. Timepoint: Added at 2014-08-03: 30 days and 2 years. Method of measurement: Added at 2014-08-03: call to patient.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzita Hajhossein Talasaz, Jamshid Salamzadeh

Tehran Heart Center, Shaheed Beheshti University of Medical Sciences

atalasaz@razi.tums.ac.ir, j.salamzadeh@yahoo.com+98 912 377 8707

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026